Could a common heart drug boost cancer treatment?
NCT ID NCT05651594
First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This study tests whether adding propranolol (a beta-blocker used for heart conditions) to standard chemotherapy and immunotherapy (pembrolizumab) can improve treatment response in people with advanced esophageal or gastroesophageal junction cancer that cannot be surgically removed. The trial aims to enroll 40 adults who have not received prior treatment for their advanced cancer. The goal is to see if propranolol can reduce stress-related immune suppression and make the cancer therapy more effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE II ESOPHAGEAL ADENOCARCINOMA AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.